Literature DB >> 30228981

Respiratory Tract Infection: A Risk Factor for the Onset and Relapse of Adult-Onset Minimal Change Disease in Southern China.

Huanqin Han1,2, Shujun Wang1, Yanting Liang3, Jieping Lin1, Lei Shi1, Lin Ye1, Shiting Song3, Minjun He3, Shihao Li3, Futong Chen3, Qingjun Pan1, Hua-Feng Liu1.   

Abstract

AIMS/
INTRODUCTION: Steroid resistance and frequent relapse are problems in the treatment of minimal change disease (MCD). However, epidemiological factors that influence steroid-resistant and relapse of MCD are rarely reported. This study evaluated potential factors that influence the onset and relapse of MCD and the epidemiological features of southern Chinese patients with adult-onset MCD. PATIENTS AND METHODS: Patients with adult-onset MCD were included from the Affiliated Hospital of Guangdong Medical University, which is located in the southernmost part of China's mainland, between 2015 and 2016. Potential influencing factors were investigated.
RESULTS: Eighty-seven patients with incipient MCD were enrolled, and 85 of these patients were followed up; 71.8% (61/85) were steroid-sensitive and 28.2% (24/85) were steroid-resistant. In terms of seasonal distribution, the highest rate of incipient cases was in spring (39.1%, 34/87), which also showed a high rate of relapse cases (29.7%, 22/74). Among patients who were followed up for more than half a year and whose proteinuria completely resolved (69.4%, 59/85), 52.5% (31/59) were without relapse and 47.5% (28/59) were with relapse. Patients without relapse were older than those with relapse (P<0.05). Before disease onset, 20.7% (18/87) of patients with incipient MCD were diagnosed with infection, including 94.5% (17/18) with respiratory tract infection. Fourteen patients in complete remission posttreatment developed an infection before relapse, including 85.7% (12/14) with respiratory tract infection.
CONCLUSION: Steroid resistance and frequent relapse are current challenges for the treatment of adult-onset MCD in southern China, and respiratory tract infection may be a risk factor for onset and relapse. Additionally, younger patients with MCD tend to have more frequent relapse.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30228981      PMCID: PMC6136503          DOI: 10.1155/2018/1657208

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


1. Introduction

Minimal change disease (MCD) is a glomerular disease clinically manifested as nephrotic syndrome (NS); the primary characteristics of MCD are no obvious pathological changes on light microscopy and extensive disappearance of podocyte foot processes on electron microscopy. Zhou et al. [1] reported that MCD accounts for 6.3%-13.4% of glomerular diseases in Chinese patients older than 14 years old. Moreover, the morbidity rate of MCD increases yearly [1]. Though patients with MCD can easily achieve remission, the relapse rate is high, and MCD can transform into focal segmental glomerulosclerosis (FSGS) or even end-stage renal disease (ESRD) [2-6]. The pathogenesis of MCD is not yet well known. Infection is one factor that is thought to potentially influence the rate of relapse of MCD; it is also the most common complication [7]. In addition, it was reported that the onset of NS in children and adolescent has a seasonal distribution [8], while the influence of seasonality on adult cases, especially adult-onset MCD, has not been reported. Most cases of MCD occur in children, and the current understanding and research of the disease are based on data derived from children. However, the incidence rate and clinical features of NS are variable according to patient age, sex, location, and race [8-12]. Moreover, factors that influence the relapse rate of MCD and the epidemiological features of adult-onset MCD are rarely reported [4, 5, 13]. In this study, patients with adult-onset MCD were included and followed up in order to investigate factors that influence the relapse rate of MCD and the epidemiological features of MCD in southern Chinese adults.

2. Materials and Methods

2.1. Patient Recruitment

This study included hospital inpatients with idiopathic MCD who were admitted to Affiliated Hospital of Guangdong Medical University, which is located in the southernmost part of China's mainland, from January 2015 to December 2016. All patients were older than 16 years old, were diagnosed with idiopathic MCD confirmed by clinical and renal pathological findings, and met the diagnostic criteria of NS. Patients with secondary MCD or idiopathic MCD combined with acute renal injury were excluded.

2.2. Therapeutic Regimen

The basic therapeutic regimen was oral prednisone 1 mg/kg/d; then, the dose was gradually reduced by 10% every 2 weeks. The total therapeutic course was approximately 9-12 months. An equal dose of methylprednisolone could be used in patients with hepatic dysfunction or hepatitis B virus infection. Corticosteroid combined with an immunosuppressant, such as cyclophosphamide, could be used in patients with steroid resistance or frequent relapse.

2.3. Study Methods

Epidemiological and clinical data of the included patients were followed up and recorded, including age, sex, therapeutic regimen, complete remission rate, time required to achieve remission, relapse rate of patients followed up for more than half a year or one year after urine protein became negative, seasonal distribution of patients with incipient and relapsed MCD, and the rate of infections before onset or during corticosteroid therapy. All data were entered into follow-up software (Siyuan Hospital Customer Relationship Management, Siyuan Technology Industrial Co., Ltd, Changsha, China) of our hospital. Potential factors (age, sex, infection) affecting primary steroid response and potential factors (age, sex, steroid sensitivity, time required to achieve remission during primary therapy) affecting relapse were analyzed, and cases with different outcomes were compared between groups.

2.4. Serum Levels of IgE Detection

Serum levels of IgE were tested with a commercial Human IgE ELISA Kit (ab108650) (Abcam, Cambridge, MA, USA). Healthy controls with no differences in age, sex, or race to idiopathic MCD patients were enrolled into the present study.

2.5. Definition

Response to steroid therapy was defined as follows: (1) steroid-sensitive: within 8 weeks after steroid therapy, urine protein became negative (negative twice not in the same day, or 24-h urine protein <0.3 g); (2) steroid-resistant: NS not achieving remission after steroid therapy for 8 weeks; (3) relapse: relapse after urine protein became negative, with urine protein ≥1+; (4) frequent relapse: ≥2 episodes of relapses in 6 months or ≥3 episodes of relapse in 1 year [5, 14].

2.6. Ethical Approval

This trial was registered with http://www.chictr.org.cn (registration number: ChiCTR-TRC-13003783) and approved by the Ethics Committee of Affiliated Hospital of Guangdong Medical University (No. PJ2017054). Consent was obtained from each participant.

2.7. Statistical Analysis

Data were analyzed using SPSS Statistics (version 23.0; IBM, USA). Data are presented as mean ± standard error or percentages. Differences were examined using Student's unpaired t-test for parametric data. Categorical data were examined using the chi-square test. The P value was considered statistically significant if less than 0.05.

3. Results

3.1. Patient Inclusion and Outcome

Figure 1 shows the flow chart of patient inclusion and outcomes, including 87 patients with incipient MCD, consisting of 75 males and 12 females ranging from 16 to 66 years old. Two patients who were transferred to other hospitals were excluded; thus 85 patients were followed up. After 8 weeks of treatment, 61 patients were steroid-sensitive and the steroid-sensitive rate (complete remission) was 71.8% (61/85) with initial therapy; 28.2% (24/85) were steroid-resistant. Patients who were followed up for less than half a year or lost during follow-up (20 patients), those who were medication noncompliant (5 patients), or those who developed spontaneous remission (1 patient) were excluded. Fifty-nine patients were followed up for more than half a year after urine protein became negative, including 52.5% (31/59) without relapse and 47.5% (28/59) with relapse (20 with frequent relapse). Of the 59 patients, 44 were followed up for more than 1 year after urine protein became negative, including 38.6% (17/44) without relapse and 61.4% (27/44) with relapse (19 with frequent relapse).
Figure 1

Flow chart of patients with minimal change disease included in the study.

3.2. Seasonal Distribution of Incipient MCD

Figure 2 shows the seasonal distribution of incipient MCD. Incipient MCD was diagnosed in 39.1% (34/87) of patients in spring, 24.1% (21/87) in winter, 20.7% (18/87) in autumn, and 16.1% (14/87) in summer. May had the most number of patients with initial onset of MCD (13, 16.1%) and October had the least (2, 2.3%).
Figure 2

Distribution of incipient minimal change disease (MCD) between 2015 and 2016. (a) Seasonal distribution of patients with incipient MCD between 2015 and 2016. (b) Monthly distribution of patients with incipient MCD between 2015 and 2016.

The relative proportion of incipient MCD (MCD case numbers divided among all admitted case numbers in the hospital) was defined due to the variability of incipient MCD cases by month, with the lowest proportion being in February, which includes Spring Festival in China, and the highest proportion in August. Results showed that the relative proportion in spring, winter, autumn, and summer gradually decreased (P = 0.016). Paired comparison showed that the relative proportion in spring was larger than that in summer (P = 0.004), autumn (P = 0.025), and winter (P = 0.158,). May was the month with the highest relative proportions (Table 1).
Table 1

Relative proportions of patients with incipient minimal change disease during each month and season.

MonthIncipient MCD (n)All admitted patients (n)Relative proportions (‰)SeasonIncipient MCD (n)All admitted patients (n)Relative proportions (‰)
Mar11130880.84Spring34390960.87
Apr9127070.71
May14133011.05
Jun6124860.48Summer14392610.36
Jul4133220.30
Aug4134530.29
Sep7120120.58Autumn17376410.48
Oct2125840.16
Nov9130450.69
Dec6127810.47  Winter21356510.59
Jan10127350.79
Feb5101350.49

MCD, minimal change disease.

3.3. Seasonal Distributions of MCD Relapse

Fifty-nine patients with incipient MCD were followed up for more than half a year from January 2015 to June 2017. Seventy-four episodes of relapse occurred, including 29.7% (22/74) in spring, 28.3% (21/74) in summer, 21.6% (16/74) in autumn, and 20.3% (15/74) in winter. The majority of relapses occurred in spring, similar to the distribution of MCD onset. Figure 3 shows the seasonal distribution of relapsed MCD.
Figure 3

Distribution of minimal change disease (MCD) relapses between 2015 and 2016. (a) Seasonal distribution of MCD relapse between 2015 and 2016. (b) Monthly distribution of MCD relapse between 2015 and 2016.

3.4. MCD and Infection

From January 2015 to June 2017, 20.7% (18/87) of patients with MCD had infection before disease onset, including 94.5% (17/18) with respiratory tract infection (including upper respiratory tract infection, bronchitis, and pulmonary infection). After complete remission and drug withdrawal, patients had infection for 14 times before relapse, including 85.7% (12/14) with respiratory tract infection. During corticosteroid therapy, 70 episodes of infection occurred; pulmonary infection (28.6%, 20/70) was most common. No patient died due to infection during follow-up. Infection sites and case numbers are reported in Table 2.
Table 2

Patients with minimal change disease with infection before onset or during corticosteroid treatment.

InfectionsBefore onsetBefore relapseDuring corticosteroid therapyTotal
Cases (n)Proportions (%)Times (n)Proportions (%)Times (n)Proportions (%)Times (n)Proportions (%)
Upper respiratory tract infection or bronchitis1161.1964.31115.73130.4
Pulmonary infection633.3321.42028.62928.4
Intestinal infection0017.11217.11312.8
Cutaneous or subcutaneous infection00001217.11211.8
Urinary infection0017.1811.498.8
 Spontaneous bacterial peritonitis15.60057.165.9
 Septicemia000022.922.0

3.5. Influence of Sex, Age, and Infection before Initial Therapy on Response to Treatment

In this study, 85 cases of incipient MCD were treated with corticosteroids. Patients were divided into steroid-sensitive and steroid-resistant groups according to the response to steroid; there was no significant difference between groups in terms of sex, age, or occurrence of infection before initial therapy (all P > 0.05) (Table 3).
Table 3

Comparisons of sex, age, and infection before initial therapy between the steroid sensitive group and resistant group.

CharacteristicSteroid sensitive (n = 61)Steroid resistant (n = 24) χ 2/t value P value
Male (n, %)54 (88.5)20 (83.3)0.0800.777
Age (x-±s, years)24.4 ± 15.922.4 ± 10.20.5870.558
With infection before onset (n, %)15 (24.6)3 (15.0)1.5080.219

3.6. Influence of Sex, Age, and Time to Initial Remission on Relapse

After urine protein became negative, 59 patients with MCD were followed up regularly for more than half a year. Among these patients, age ranged from 18 to 49 years old, and the average follow-up duration was 55.1 ± 32.9 weeks. Table 4 reports correlations of sex, age, steroid sensitivity at initial therapy, and time required to achieve remission after initial therapy with later relapse; results suggest that the nonrelapse group included more patients of older age than the relapse group (P < 0.05). No significant difference was observed between sex, steroid sensitivity, and time required to achieve remission after initial therapy (all P > 0.05).
Table 4

Comparisons of sex, age, steroid sensitivity, and time to complete remission after initial therapy between the non-relapse group and relapse group.

CharacteristicNon-relapsers (n = 31)Relapsers (n = 28) χ 2/t value P value
Male (n, %)27 (87.1)25 (89.3)0.0001.000
Age (x-±s, years)22.9 ± 9.418.8 ± 4.12.1830.035
Steroid sensitive (n, %)26 (83.9)23 (82.1)0.0001.000
Time required to achieve remission (x-±s, w)5.7±4.85.1±4.40.5320.597
For 28 patients in the relapse group, 20 cases showed frequent relapse and 8 cases showed infrequent relapse, with mean ages of 18.5 ± 4.3 and 19.5 ± 3.9 years old, respectively. The mean age of the infrequent relapse group was slightly older than that of the frequent relapse group, although this was not statistically significant (t = 0.575, P = 0.570).

3.7. Serum Levels of IgE in Incipient MCD

The results showed that serum IgE levels in patients with MCD (371.8 ± 248.5 IU/ml) (n = 87) were significantly higher than in the normal control group (47.2 ± 31.6 IU/ml) (n = 36; 31 male, 5 females; Age: 21.8 ± 13.6 years) (P < 0.05).

4. Discussion

The incidence rate and clinical features of NS are recognized to be variable according to patient age, sex, location, and race [8-12]. In the current study, patients were from the Affiliated Hospital of Guangdong Medical University, which is located in the southernmost part of China's mainland, a region with a tropical and subtropical monsoon climate and hot and humid weather. The patients included in this study were diagnosed with adult-onset MCD. Our study suggests that most patients with adult-onset MCD show good response to corticosteroid treatment, in agreement with reports from other regions [3, 4]. The relapse rate of adult MCD after remission may be lower than that of children, but there is a lack of high-quality medical evidence. In this study, after urine protein became negative, 59 patients were followed up for more than half a year with a relapse rate of 47.5%; the relapse rate increased to 61.4% with one year follow-up. Compared to the typical and high-quality research data concerning relapse of children with MCD conducted by Tarshish et al. [15], it seems that long-term remission in adult patients was not higher than that of children. We analyzed the seasonal features of incipient and relapsed MCD to investigate the external factors associated with MCD onset in this patient group. We found that incipient MCD shows seasonal differences; the incidence rate is highest in the spring, followed by winter. Similarly, Chang et al. [8] analyzed 4083 cases of primary NS in children and adolescence in Taiwan and found that incipient diseases occurred most commonly in winter, followed by spring. In fact, most cases of MCD relapse also occurred in the spring, though there was no significant difference among seasons. In our opinion, the difference in seasonality between incipient and relapse MCD may be due to many factors. Not only season, but also climate, individual immunity, patient compliance, and infection rate may influence the relapse trends. As adult MCD shows obvious seasonal differences, we assumed that the high incidence rates of MCD in spring and winter may be due to high rates of respiratory tract infection during these two seasons, and upper respiratory tract infection may be an important cause of MCD onset. Second, MCD may be a disease related to allergy, and its activity is associated with increased serum IgE levels [16-19], an antibody that mediates allergy. In fact, in this study, we also found that serum IgE levels in patients with MCD were significantly higher than in the normal control group. Additionally, spring is the season with the high rates of allergic diseases, such as allergic rhinitis and bronchial asthma [20]. Thus, the high rates of MCD in the spring and winter in the current study further suggest that MCD may be a disease associated with infection and allergy. This phenomenon also suggests that we should include analysis of allergic factors, such as IgE, basophils, and eosinophils, when studying the pathogenesis of MCD. Infection is one of the main causes of relapse and poor treatment efficacy in patients with NS. MCD, which presents as NS, may be complicated by infection because of obviously lower IgG levels, immune dysfunction [21], subcutaneous effusion [22], and use of corticosteroids. However, these data are mainly acquired from children. Our study indicates that incipient and relapsed adult MCD are usually associated with previous infection, especially respiratory tract infection. More importantly, many patients have edema and massive proteinuria following respiratory tract infection; it is presumed that infection is not only a complication of MCD, but also a reason for the development of incipient or relapsed MCD. Thus it would be very beneficial for patients with MCD to avoid respiratory tract infection. Up to now, studies on the response of NS to steroids and the NS relapse rate have primarily been performed in children, with very few investigations of adults, and extremely rare studies enrolling Chinese adults. However, it is known that predicting steroid response and relapse in patients with MCD is of concern. Here, we analyzed the basic information of patients in steroid-sensitive and steroid-resistant groups, but did not identify any influence of sex, age, or initial therapy on steroid sensitivity. We also analyzed factors influencing MCD relapse in adult patients, but again did not find an effect of sex, steroid sensitivity at initial therapy, or time required to achieve remission after initial therapy. However, age was significantly association with relapse, as younger adult patients tended to show relapse or frequent relapse, but older patients tended not to relapse. These findings, based on our large patient sample size, were similar to another reported by Tse et al. [23]

5. Conclusions

Steroid resistance and frequent relapse are current challenges for the treatment of adult-onset MCD in southern China, and respiratory tract infection may be a risk factor for the onset and relapse of MCD in these patients. Younger patients with MCD are more likely to relapse or show frequent relapse.
  23 in total

1.  Elevated levels of immunoglobulin E may indicate steroid resistance or relapse in adult primary nephrotic syndrome, especially in minimal change nephrotic syndrome.

Authors:  Y Tan; D Yang; J Fan; Y Chen
Journal:  J Int Med Res       Date:  2011       Impact factor: 1.671

Review 2.  The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies.

Authors:  Wagner de Fátima Pereira; Gustavo Eustáquio Alvim Brito-Melo; Fábio Tadeu Lourenço Guimarães; Thiago Guimarães Rosa Carvalho; Elvis Cueva Mateo; Ana Cristina Simões e Silva
Journal:  Inflamm Res       Date:  2014-01       Impact factor: 4.575

3.  Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort study.

Authors:  Maki Shinzawa; Ryohei Yamamoto; Yasuyuki Nagasawa; Susumu Oseto; Daisuke Mori; Kodo Tomida; Terumasa Hayashi; Masaaki Izumi; Megumu Fukunaga; Atsushi Yamauchi; Yoshiharu Tsubakihara; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2013-03-20       Impact factor: 2.801

4.  Premature mortality due to nephrotic syndrome and the trend in nephrotic syndrome mortality in Japan, 1995-2014.

Authors:  Minako Wakasugi; Junichiro James Kazama; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2017-05-06       Impact factor: 2.801

5.  Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome.

Authors:  Masaru Nakayama; Ritsuko Katafuchi; Tetsuro Yanase; Kiyoshi Ikeda; Hiroshi Tanaka; Satoru Fujimi
Journal:  Am J Kidney Dis       Date:  2002-03       Impact factor: 8.860

6.  The incidence of the nephrotic syndrome in childhood in Germany.

Authors:  Ingo Franke; Malik Aydin; Corinna Elke Llamas Lopez; Lisa Kurylowicz; Rainer Ganschow; Michael Lentze; Mark Born
Journal:  Clin Exp Nephrol       Date:  2017-06-22       Impact factor: 2.801

7.  Adult-onset minimal change nephrotic syndrome: a long-term follow-up.

Authors:  F Nolasco; J S Cameron; E F Heywood; J Hicks; C Ogg; D G Williams
Journal:  Kidney Int       Date:  1986-06       Impact factor: 10.612

Review 8.  Idiopathic nephrotic syndrome and atopy: is there a common link?

Authors:  Maher Abdel-Hafez; Michiko Shimada; Pui Y Lee; Richard J Johnson; Eduardo H Garin
Journal:  Am J Kidney Dis       Date:  2009-06-25       Impact factor: 8.860

9.  Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses.

Authors:  Kai-Chung Tse; Man-Fei Lam; Pok-Siu Yip; Fu-Keung Li; Bo-Ying Choy; Kar-Neng Lai; Tak-Mao Chan
Journal:  Nephrol Dial Transplant       Date:  2003-07       Impact factor: 5.992

Review 10.  Interventions for minimal change disease in adults with nephrotic syndrome.

Authors:  S C Palmer; K Nand; G F Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23
View more
  3 in total

1.  Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study.

Authors:  Ryohei Yamamoto; Enyu Imai; Shoichi Maruyama; Hitoshi Yokoyama; Hitoshi Sugiyama; Asami Takeda; Tatsuo Tsukamoto; Shunya Uchida; Kazuhiko Tsuruya; Tatsuya Shoji; Hiroki Hayashi; Yasuhiro Akai; Megumu Fukunaga; Tsuneo Konta; Saori Nishio; Shunsuke Goto; Hirofumi Tamai; Kojiro Nagai; Ritsuko Katafuchi; Kosuke Masutani; Takashi Wada; Tomoya Nishino; Arimasa Shirasaki; Hiroshi Sobajima; Kosaku Nitta; Kunihiro Yamagata; Junichiro J Kazama; Keiju Hiromura; Hideo Yasuda; Makoto Mizutani; Toshiyuki Akahori; Tomohiko Naruse; Takeyuki Hiramatsu; Kunio Morozumi; Tetsushi Mimura; Yosuke Saka; Eiji Ishimura; Hajime Hasegawa; Daisuke Ichikawa; Takashi Shigematsu; Hiroshi Sato; Ichiei Narita; Yoshitaka Isaka
Journal:  J Nephrol       Date:  2022-04-02       Impact factor: 3.902

Review 2.  Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome.

Authors:  Stefano Turolo; Alberto Edefonti; Alessandra Mazzocchi; Marie Louise Syren; William Morello; Carlo Agostoni; Giovanni Montini
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

3.  Increased number and activation of peripheral basophils in adult-onset minimal change disease.

Authors:  Huanqin Han; Yong-Zhi Xu; Shuzhen Liao; Haiyan Xiao; Xiaoqun Chen; Xing Lu; Shujun Wang; Chen Yang; Hua-Feng Liu; Qingjun Pan
Journal:  J Cell Mol Med       Date:  2020-06-08       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.